Inactive

Biomedical Advanced Research and Development Authority (BARDA) has a current Area of Interest (AoI) W911QY-20-S-C001-A002 COVID-19 for Neutralization Assay Services. Identifying and procuring this nee... Biomedical Advanced Research and Development Authority (BARDA) has a current Area of Interest (AoI) W911QY-20-S-C001-A002 COVID-19 for Neutralization Assay Services. Identifying and procuring this need is imperative as BARDA-sponsored product developers and manufacturers may not have timely access to this service for COVID-19 response. To that end the government seeks services allowing for technology transfer of a high throughput qualified or validated neutralization assay for SARS-COV-2 in a Biosafety Level 3 (BSL3) laboratory to a new site in compliance with GCLP (Contract Base period) and subsequent validation. Additionally, the government requires testing of serum samples from human subjects enrolled in clinical trials of COVID-19 vaccines using the new validated assay in compliance with GCLP. In accordance with the attached AoI, Solution Briefs must be submitted no later than 1200 on 31 July, 2020.